Direct Economic Burden and Influencing Factors in Patients With Hepatitis B Virus Related Diseases in Jiangsu, China

Zhang, Hua; Chao, Jianqian; Zhu, Liguo; Song, Long; Li, Xiyan; Liu, Pei

doi:10.1177/1010539514560057

Cited by 13 publications

(11 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, in 2020, hepatitis imposed a heavy economic burden on HBV sufferers, their families and the society [ 26 ]. In Shandong province, Lu et al estimated the inpatient medical costs of hepatitis B-related diseases ranged from $US2954 to $US10,635 per patient and Zhang et al found that in Jiangsu province the direct economic costs of HBV-related diseases ranged from $US107 for outpatients to $US3193 for inpatients [ 27 , 28 ]. These prevalence rates and public health costs call for expanded vaccinations of susceptible adults and the need for public health officials to intervene to reduce hepatitis B infections in adults.…”

Section: Introductionmentioning

confidence: 99%

Behavioral Differences in the Preference for Hepatitis B Virus Vaccination: A Discrete Choice Experiment

et al. 2020

View full text Add to dashboard Cite

Understanding behavioral factors differences in the preferences for vaccinations can improve predictions of vaccine uptake rates and identify effective policy interventions to increase the demand for vaccinations. In this study, 353 adults in Shandong province in China were interviewed about their preferences for hepatitis B virus (HBV) vaccination. A discrete choice experiment (DCE) was employed to analyze the preference for HBV vaccinations, and a mixed logit model was used to estimate respondent preferences for vaccination attributes included in the DCE. While the protection rate against hepatitis B (HB), duration of protection, risk of side-effects, and vaccination cost were shown to influence adults’ preferences for HBV vaccination, adults valued “99% hepatitis B protection” above other attributes, followed by “20 years’ protection duration” and “1 in 150,000 risk of side-effects”. Individuals with lower time discount rates, non-overconfidence, or higher risk aversion were more likely to choose a vaccine. Lower risk aversion individuals showed a higher preference for lower risk of side-effects. Lower time discount rate individuals showed a higher preference for longer protection duration. Non-overconfidence individuals showed a higher preference for higher hepatitis B protection and cost. Interventions should be targeted to the behavioral determinants impeding vaccination.

show abstract

Section: Introductionmentioning

confidence: 99%

Behavioral Differences in the Preference for Hepatitis B Virus Vaccination: A Discrete Choice Experiment

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In Shandong province, Lu et al estimated the in-patient costs of hepatitis B-related diseases ranged from $US2954 to $US10635 per patient, 5 and Zhang et al found that in Jiangsu province the direct economic costs of HBV-related diseases ranged from $US107 for out-patients to $US3193 for in-patients. 6 All these studies advocated the need for public health officials to intervene to reduce HBV-related diseases.…”

Section: Introductionmentioning

confidence: 99%

Factors associated with adults' perceived need to vaccinate against hepatitis B in rural China

Wang

Wangen

et al. 2016

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Hepatitis B virus (HBV) infection is a serious public-health issue in China. While the hepatitis B vaccine is effective in preventing HBV infection, the HBV vaccination coverage rates among Chinese adults remain low. From a survey of rural adults from 7 provinces in China, we identified a unique HBV at-risk group: rural adults who had no history of HBV vaccination and had no plan to HBV vaccinate in the future. We divided this 'no history-no plan' group into those who identified No-need to vaccinate and those that perceived a Need to vaccinate (even if they had no plan to do so). We found age, marital status, health status, perceived HBV infection environment, perceived HBV infection risk and perceived HBV infection severity explained differences between the 'No-need' and 'Need" to HBV vaccinate groups. Education, occupation and knowledge of hepatitis B and HBV transmission were not associated with HBV vaccination need. Our results showed that free HBV vaccinations and reimbursement for vaccinating could significantly increase the HBV vaccinate take-up rate for both Need and No-need rural adults. A tailored public health HBV campaign, especially targeting the No-need subgroup, would increase vaccination rates by better informing rural adults about HBV transmission routes, the dangers of HBV infection, the effectiveness of HBV vaccinations and the safety of HBV vaccinations.

show abstract

“…Annual cost of LVD (GlaxoSmithKline Ltd.) was US $865.39,ETV(Shanghai Squibb Company) was US $2006.57.Annual direct medical costs for managing these CHB-related disease states were derived from our previous study[30]. CHB: $4257.84, CC: $3910.69, DC: $6434.70, HCC: $4874.21.…”

Section: Methodsmentioning

confidence: 99%

Application of Bayesian Approach to Cost-Effectiveness Analysis of Antiviral Treatments in Chronic Hepatitis B

2016

Self Cite

View full text Add to dashboard Cite

BackgroundHepatitis B virus (HBV) infection is a major problem for public health; timely antiviral treatment can significantly prevent the progression of liver damage from HBV by slowing down or stopping the virus from reproducing. In the study we applied Bayesian approach to cost-effectiveness analysis, using Markov Chain Monte Carlo (MCMC) simulation methods for the relevant evidence input into the model to evaluate cost-effectiveness of entecavir (ETV) and lamivudine (LVD) therapy for chronic hepatitis B (CHB) in Jiangsu, China, thus providing information to the public health system in the CHB therapy.MethodsEight-stage Markov model was developed, a hypothetical cohort of 35-year-old HBeAg-positive patients with CHB was entered into the model. Treatment regimens were LVD100mg daily and ETV 0.5 mg daily. The transition parameters were derived either from systematic reviews of the literature or from previous economic studies. The outcome measures were life-years, quality-adjusted lifeyears (QALYs), and expected costs associated with the treatments and disease progression. For the Bayesian models all the analysis was implemented by using WinBUGS version 1.4.ResultsExpected cost, life expectancy, QALYs decreased with age. Cost-effectiveness increased with age. Expected cost of ETV was less than LVD, while life expectancy and QALYs were higher than that of LVD, ETV strategy was more cost-effective. Costs and benefits of the Monte Carlo simulation were very close to the results of exact form among the group, but standard deviation of each group indicated there was a big difference between individual patients.ConclusionsCompared with lamivudine, entecavir is the more cost-effective option. CHB patients should accept antiviral treatment as soon as possible as the lower age the more cost-effective. Monte Carlo simulation obtained costs and effectiveness distribution, indicate our Markov model is of good robustness.

show abstract

Direct Economic Burden and Influencing Factors in Patients With Hepatitis B Virus Related Diseases in Jiangsu, China

Cited by 13 publications

References 13 publications

Behavioral Differences in the Preference for Hepatitis B Virus Vaccination: A Discrete Choice Experiment

Behavioral Differences in the Preference for Hepatitis B Virus Vaccination: A Discrete Choice Experiment

Factors associated with adults' perceived need to vaccinate against hepatitis B in rural China

Application of Bayesian Approach to Cost-Effectiveness Analysis of Antiviral Treatments in Chronic Hepatitis B

Contact Info

Product

Resources

About